DOVER — There were significant discoveries regarding Alzheimer’s disease in 2023.
And now, with advancements in treatment research, risk factors and diagnosis of the disease, patients in the First State and around the country may soon be able to better control the condition.
According to the Alzheimer’s Association, there are three new treatments for the disease, and a fourth one is on the way.
The U.S. FDA granted approval to Leqembi in July 2023 for those experiencing mild cognitive impairment due to Alzheimer’s disease, and while the treatment is not a cure, it slows cognitive decline and delays the onset of symptoms.
In May, the FDA approved Brexpiprazole for individuals who deal with agitation as a result of the disease, the first federally approved treatment for such symptoms, which are experienced by about 45% of Alzheimer’s patients, according to the association.
The approval of Leqembi came after the three-phase clinical study process before being approved by the FDA. The Alzheimer’s Association reported that the drug is the second monoclonal antibody treatment to receive approval since 2021.